(CL) Colgate-Palmolive - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1941621039
Stock:
Total Rating 65
Risk 89
Buy Signal 0.45
| Risk 5d forecast | |
|---|---|
| Volatility | 22.3% |
| Relative Tail Risk | -2.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.33 |
| Alpha | 5.85 |
| Character TTM | |
|---|---|
| Beta | 0.039 |
| Beta Downside | -0.039 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.05% |
| CAGR/Max DD | 0.44 |
EPS (Earnings per Share)
Revenue
Description: CL Colgate-Palmolive
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.13b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 0.15 > 1.0 |
| NWC/Revenue: -0.13% < 20% (prev -2.20%; Δ 2.07% < -1%) |
| CFO/TA 0.26 > 3% & CFO 4.20b > Net Income 2.13b |
| Net Debt (6.70b) to EBITDA (3.77b): 1.78 < 3 |
| Current Ratio: 1.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (804.7m) vs 12m ago -2.16% < -2% |
| Gross Margin: 60.11% > 18% (prev 0.61%; Δ 5950 % > 0.5%) |
| Asset Turnover: 125.9% > 50% (prev 125.3%; Δ 0.64% > 0%) |
| Interest Coverage Ratio: 11.73 > 6 (EBITDA TTM 3.77b / Interest Expense TTM 268.0m) |
Altman Z'' 6.70
| A: -0.00 (Total Current Assets 5.71b - Total Current Liabilities 5.74b) / Total Assets 16.33b |
| B: 1.66 (Retained Earnings 27.05b / Total Assets 16.33b) |
| C: 0.19 (EBIT TTM 3.14b / Avg Total Assets 16.19b) |
| D: 0.00 (Book Value of Equity 54.0m / Total Liabilities 15.96b) |
| Altman-Z'' Score: 6.70 = AAA |
Beneish M -3.11
| DSRI: 1.09 (Receivables 1.68b/1.52b, Revenue 20.38b/20.10b) |
| GMI: 1.01 (GM 60.11% / 60.51%) |
| AQI: 0.93 (AQ_t 0.37 / AQ_t-1 0.39) |
| SGI: 1.01 (Revenue 20.38b / 20.10b) |
| TATA: -0.13 (NI 2.13b - CFO 4.20b) / TA 16.33b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of CL shares?
As of March 03, 2026, the stock is trading at USD 97.30 with a total of 6,273,312 shares traded.
Over the past week, the price has changed by +0.21%, over one month by +5.89%, over three months by +24.20% and over the past year by +7.42%.
Over the past week, the price has changed by +0.21%, over one month by +5.89%, over three months by +24.20% and over the past year by +7.42%.
Is CL a buy, sell or hold?
Colgate-Palmolive has received a consensus analysts rating of 3.77.
Therefor, it is recommend to hold CL.
- StrongBuy: 7
- Buy: 6
- Hold: 7
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the CL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96.7 | -0.6% |
| Analysts Target Price | 96.7 | -0.6% |
CL Fundamental Data Overview February 28, 2026
P/E Trailing = 37.0913
P/E Forward = 24.7525
P/S = 3.8682
P/B = 1443.0055
P/EG = 3.6985
Revenue TTM = 20.38b USD
EBIT TTM = 3.14b USD
EBITDA TTM = 3.77b USD
Long Term Debt = 7.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, two quarters ago)
Debt = 7.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.70b USD (from netDebt column, last quarter)
Enterprise Value = 85.54b USD (78.84b + Debt 7.99b - CCE 1.29b)
Interest Coverage Ratio = 11.73 (Ebit TTM 3.14b / Interest Expense TTM 268.0m)
EV/FCF = 23.54x (Enterprise Value 85.54b / FCF TTM 3.63b)
FCF Yield = 4.25% (FCF TTM 3.63b / Enterprise Value 85.54b)
FCF Margin = 17.83% (FCF TTM 3.63b / Revenue TTM 20.38b)
Net Margin = 10.46% (Net Income TTM 2.13b / Revenue TTM 20.38b)
Gross Margin = 60.11% ((Revenue TTM 20.38b - Cost of Revenue TTM 8.13b) / Revenue TTM)
Gross Margin QoQ = 60.15% (prev 59.42%)
Tobins Q-Ratio = 5.24 (Enterprise Value 85.54b / Total Assets 16.33b)
Interest Expense / Debt = 0.80% (Interest Expense 64.0m / Debt 7.99b)
Taxrate = 26.09% (798.0m / 3.06b)
NOPAT = 2.32b (EBIT 3.14b * (1 - 26.09%))
Current Ratio = 1.00 (Total Current Assets 5.71b / Total Current Liabilities 5.74b)
Debt / Equity = 147.9 (Debt 7.99b / totalStockholderEquity, last quarter 54.0m)
Debt / EBITDA = 1.78 (Net Debt 6.70b / EBITDA 3.77b)
Debt / FCF = 1.84 (Net Debt 6.70b / FCF TTM 3.63b)
Total Stockholder Equity = 493.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.16% (Net Income 2.13b / Total Assets 16.33b)
RoE = 431.6% (Net Income TTM 2.13b / Total Stockholder Equity 493.8m)
RoCE = 37.07% (EBIT 3.14b / Capital Employed (Equity 493.8m + L.T.Debt 7.99b))
RoIC = 25.47% (NOPAT 2.32b / Invested Capital 9.12b)
WACC = 5.56% (E(78.84b)/V(86.83b) * Re(6.06%) + D(7.99b)/V(86.83b) * Rd(0.80%) * (1-Tc(0.26)))
Discount Rate = 6.06% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.24%
[DCF] Terminal Value 87.29% ; FCFF base≈3.60b ; Y1≈3.98b ; Y5≈5.17b
[DCF] Fair Price = 180.9 (EV 152.55b - Net Debt 6.70b = Equity 145.85b / Shares 806.1m; r=5.90% [WACC]; 5y FCF grow 12.34% → 2.90% )
EPS Correlation: 93.07 | EPS CAGR: 6.89% | SUE: 1.95 | # QB: 1
Revenue Correlation: 91.01 | Revenue CAGR: 4.72% | SUE: 2.24 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.97 | Chg7d=+0.000 | Chg30d=+0.014 | Revisions Net=+9 | Analysts=16
EPS current Year (2026-12-31): EPS=3.88 | Chg7d=-0.000 | Chg30d=+0.039 | Revisions Net=+11 | Growth EPS=+5.1% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=4.14 | Chg7d=-0.000 | Chg30d=+0.043 | Revisions Net=+6 | Growth EPS=+6.8% | Growth Revenue=+3.4%
[Analyst] Revisions Ratio: +1.00 (9 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = -0.9% (Analyst 4.3% - Implied 5.3%)
P/E Forward = 24.7525
P/S = 3.8682
P/B = 1443.0055
P/EG = 3.6985
Revenue TTM = 20.38b USD
EBIT TTM = 3.14b USD
EBITDA TTM = 3.77b USD
Long Term Debt = 7.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, two quarters ago)
Debt = 7.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.70b USD (from netDebt column, last quarter)
Enterprise Value = 85.54b USD (78.84b + Debt 7.99b - CCE 1.29b)
Interest Coverage Ratio = 11.73 (Ebit TTM 3.14b / Interest Expense TTM 268.0m)
EV/FCF = 23.54x (Enterprise Value 85.54b / FCF TTM 3.63b)
FCF Yield = 4.25% (FCF TTM 3.63b / Enterprise Value 85.54b)
FCF Margin = 17.83% (FCF TTM 3.63b / Revenue TTM 20.38b)
Net Margin = 10.46% (Net Income TTM 2.13b / Revenue TTM 20.38b)
Gross Margin = 60.11% ((Revenue TTM 20.38b - Cost of Revenue TTM 8.13b) / Revenue TTM)
Gross Margin QoQ = 60.15% (prev 59.42%)
Tobins Q-Ratio = 5.24 (Enterprise Value 85.54b / Total Assets 16.33b)
Interest Expense / Debt = 0.80% (Interest Expense 64.0m / Debt 7.99b)
Taxrate = 26.09% (798.0m / 3.06b)
NOPAT = 2.32b (EBIT 3.14b * (1 - 26.09%))
Current Ratio = 1.00 (Total Current Assets 5.71b / Total Current Liabilities 5.74b)
Debt / Equity = 147.9 (Debt 7.99b / totalStockholderEquity, last quarter 54.0m)
Debt / EBITDA = 1.78 (Net Debt 6.70b / EBITDA 3.77b)
Debt / FCF = 1.84 (Net Debt 6.70b / FCF TTM 3.63b)
Total Stockholder Equity = 493.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.16% (Net Income 2.13b / Total Assets 16.33b)
RoE = 431.6% (Net Income TTM 2.13b / Total Stockholder Equity 493.8m)
RoCE = 37.07% (EBIT 3.14b / Capital Employed (Equity 493.8m + L.T.Debt 7.99b))
RoIC = 25.47% (NOPAT 2.32b / Invested Capital 9.12b)
WACC = 5.56% (E(78.84b)/V(86.83b) * Re(6.06%) + D(7.99b)/V(86.83b) * Rd(0.80%) * (1-Tc(0.26)))
Discount Rate = 6.06% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.24%
[DCF] Terminal Value 87.29% ; FCFF base≈3.60b ; Y1≈3.98b ; Y5≈5.17b
[DCF] Fair Price = 180.9 (EV 152.55b - Net Debt 6.70b = Equity 145.85b / Shares 806.1m; r=5.90% [WACC]; 5y FCF grow 12.34% → 2.90% )
EPS Correlation: 93.07 | EPS CAGR: 6.89% | SUE: 1.95 | # QB: 1
Revenue Correlation: 91.01 | Revenue CAGR: 4.72% | SUE: 2.24 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.97 | Chg7d=+0.000 | Chg30d=+0.014 | Revisions Net=+9 | Analysts=16
EPS current Year (2026-12-31): EPS=3.88 | Chg7d=-0.000 | Chg30d=+0.039 | Revisions Net=+11 | Growth EPS=+5.1% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=4.14 | Chg7d=-0.000 | Chg30d=+0.043 | Revisions Net=+6 | Growth EPS=+6.8% | Growth Revenue=+3.4%
[Analyst] Revisions Ratio: +1.00 (9 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = -0.9% (Analyst 4.3% - Implied 5.3%)